316 related articles for article (PubMed ID: 21390475)
1. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Mahévas T; Arnulf B; Bouaziz JD; Livideanu CB; Osio A; Servy A; Cribier B; Sassolas B; Jachiet M; Michel L; Aucouturier P; Lipsker D; Frances C; Sbidian E; Rybojad M; Descamps V; D'Incan M; Humbert P; Beylot-Barry M; Passeron T; de Moreuil C; Taha RY; Hermine O; Dupuy A; Barbarot S; Debarbieux S; Carpentier O; Brault F; Schmutz JL; Thomas-Beaulieu D; Modiano P; Zarnitsky C; Lifermann F; Baubion E; Limal N; Le Bras F; Le Moigne M; Tauber M; Talbot A; Prud'homme R; Peltier S; De Masson A; Battistella M; Bagot M; Mékinian A; Fain O
Blood; 2020 Apr; 135(14):1101-1110. PubMed ID: 32027747
[TBL] [Abstract][Full Text] [Related]
3. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
4. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.
Letzelter M; Grimaux X
Acta Dermatovenerol Croat; 2021 Apr; 291(1):51-53. PubMed ID: 34477065
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
[TBL] [Abstract][Full Text] [Related]
8. Acute Encephalitic Syndrome Induced by Scleromyxedema.
Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
10. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
Körber A; Franckson T; Grabbe S; Dissemond J
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
[No Abstract] [Full Text] [Related]
11. Scleromyxedema with histology resembling granuloma annulare.
Mullangi S; Granter SR; Laubach JP; Lipworth AD
Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780962
[TBL] [Abstract][Full Text] [Related]
12. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.
Delyon J; Bézier M; Rybojad M; Brière J; Validire P; Bagot M; Janin A; Battistella M
Virchows Arch; 2013 Jun; 462(6):679-83. PubMed ID: 23681113
[TBL] [Abstract][Full Text] [Related]
13. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Efthimiou P; Blanco M
Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
[TBL] [Abstract][Full Text] [Related]
14. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare.
Rongioletti F; Cozzani E; Parodi A
J Cutan Pathol; 2010 Oct; 37(10):1084-7. PubMed ID: 19638067
[TBL] [Abstract][Full Text] [Related]
15. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
Bidier M; Zschoche C; Gholam P; Enk AH; Hadaschik EN
Acta Derm Venereol; 2012 Jul; 92(4):408-9. PubMed ID: 22278389
[No Abstract] [Full Text] [Related]
16. [Response to thalidomide in scleromyxedema].
Pascualini MF; Caballero Escuti G; Valente E; Kurpis M; Ruiz Lascano A
Medicina (B Aires); 2013; 73(3):252-4. PubMed ID: 23732202
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of scleromyxoedema in an Afro-Caribbean man.
Ufodiama CE; Tynes G; Unwala R
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30665930
[No Abstract] [Full Text] [Related]
18. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
19. Scleromyxedema without paraproteinemia.
Abarzúa AA; Giesen LF; Sandoval MO; González SB
Int J Dermatol; 2014 Aug; 53(8):971-4. PubMed ID: 24527753
[TBL] [Abstract][Full Text] [Related]
20. [Good response of scleromyxedema and dermato-neuro syndrome to treatment with intravenous immunoglobulins].
Bielsa I; Benvenutti F; Guinovart RM; Ferrándiz C
Actas Dermosifiliogr; 2012 May; 103(4):317-20. PubMed ID: 21917233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]